Les Funtleyder is a longtime health care investor who started his professional investing career just over two decades ago. Today, he is a health care portfolio manager at E Squared Capital Management in New York. He’s also an author of the book called “Health Care Investing.” He was in Boston recently to give a guest lecture at Tufts University and he stopped by STAT’s offices for a chat about the current and future state of health care investing.

We want you to compare and contrast biotech investing today versus when you started on Wall Street. The science, of course, has gotten a lot more complex. So how do you adapt?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy